TEAMLAB
8.8.2019 12:48:06 CEST | Business Wire | Press release
This summer marks the one-year anniversaries for art collective teamLab’s two museums in Tokyo: MORI Building DIGITAL ART MUSEUM: teamLab Borderless (Odaiba, Tokyo; hereafter teamLab Borderless) and teamLab Planets TOKYO (Toyosu, Tokyo; hereafter teamLab Planets). In the one year since their openings, teamLab Borderless and teamLab Planets have seen a combined 3.5 million visitors. teamLab Borderless alone welcomed 2.3 million visitors within one year of opening, exceeding the number of attendees at the Van Gogh Museum in the Netherlands and setting a record number of visitors at a single-artist museum in one year. These visitors came from over 160 countries and regions around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190808005373/en/
teamLab Borderless and teamLab Planets are two museums dedicated solely to art by teamLab. teamLab Borderless is a world of ever-changing artworks without boundaries, a “museum without a map.” One year since its opening in June, 2018, the museum has seen approximately 2.3 million visitors from over 160 countries and regions worldwide. teamLab Planets is “a museum where you move through water.” Guests walk barefoot in the space and physically immerse their entire bodies in massive artworks. One year since its opening in July, 2018, the museum has welcomed over 1.25 million visitors from 106 countries and regions around the world.
When compared to the world’s three most-visited single-artist museums of 2018, both teamLab Borderless and teamLab Planets welcomed more visitors than the Picasso Museum in Barcelona, Spain (948,483 visitors), and the Dalí Theatre-Museum in Figueres, Spain (1,105,169 visitors). The number of museum attendees at teamLab Borderless exceeds even those of the Van Gogh Museum in Amsterdam, Netherlands (2,161,160 visitors), making it the world’s most-visited museum dedicated to a single artist. (*1).
- teamLab Borderless (Odaiba, Tokyo)
Of the 2.3 million visitors to teamLab Borderless, approximately 50% come from overseas (*2), with most coming from the USA, followed by Australia, China, Thailand, Canada, and the UK, making it a museum that attracts not only visitors from neighboring countries, but those from far more distant regions as well. In addition, according to a survey conducted by the museum, it appears that about 50% of the guests from overseas visited Tokyo in order to visit the museum (*3).
- teamLab Planets (Toyosu, Tokyo)
Of the 1.25 million visitors to teamLab Planets, approximately 30% come from overseas (*4), with the majority coming from the USA, followed by Hong Kong, Taiwan, the UK, and Australia.
-----------------------
*1 ”THE ART NEWSPAPER SPECIAL REPORT Art’s Most Popular: Exhibition and museum visitor figures 2018” The Art Newspaper. Number 311, April, 2019.
*2 teamLab Borderless Official Website, Ticket Purchasing Data (data obtained Feb 16 - June 7, 2019)
*3 teamLab Borderless Visitor Survey (conducted Oct 25 - Nov 2, 2018), 1,237 respondents
*4 teamLab Planets Official Website, Ticket Purchasing Data (data obtained March 1 - June 30, 2019)
About teamLab
teamLab (f. 2001) is an art collective, interdisciplinary group of ultratechnologists whose collaborative practice seeks to navigate the confluence of art, science, technology, design and the natural world. teamLab aims to explore a new relationship between humans and nature, and between oneself and the world through art. Click here
for full bio.
teamLab is represented by Pace Gallery
.
Press Kit
teamLab Borderless
https://goo.gl/MpzVss
For tickets and more information, please visit borderless.teamlab.art
, and follow Instagram
.
teamLab Planets
https://goo.gl/tQXMLm
For tickets and more information, please visit planets.teamlab.art
, and follow Instagram
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190808005373/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom